Table 1 Baseline characteristics of the derivation cohort and validation cohort
Variables | Derivation cohort (n = 75) | Validation cohort (n = 30) | P |
|---|---|---|---|
Gender (%) | |||
Male/female | 19/56 | 6/24 | 0.740 |
Age | 49.03 ± 11.70 | 44.97 ± 12.68 | 0.140 |
Pathologic basis (%) | |||
CHB | 53 (70.67%) | 18 (60%) | |
HBC | 22 (29.33%) | 12 (40%) | 0.410 |
ALB (g/L) | 31.61 ± 5.13 | 31.46 ± 5.35 | 0.930 |
TBIL (umol/L) | 314.38 ± 104.00 | 328.73 ± 147.91 | 0.980 |
Na (mmol/L) | 136.48 ± 3.94 | 135.01 ± 4.59 | 0.140 |
Cr (umol/L) | 84.89 ± 61.13 | 80.05 ± 33.36 | 0.530 |
BUN (mmol/L) | 6.33 ± 5.40 | 5.86 ± 2.59 | 0.480 |
CHE (U/L) | 4012.60 ± 1506.31 | 3936.47 ± 1735.93 | 0.800 |
eGFR (ml/min) | 98.03 ± 30.37 | 100.57 ± 32.53 | 0.720 |
INR | 2.53 ± 1.31 | 2.72 ± 0.98 | 0.098 |
Lactate | 2.10 ± 1.58 | 2.30 ± 1.26 | 0.260 |
MAP | 84.11 ± 10.70 | 85.90 ± 10.11 | 0.260 |
HBV-DNA | 7.70E + 04 (2.04E + 03,6.75E + 07) | 2.39E + 05 (2.63E + 04,1.08E + 08) | 0.120 |
HE | |||
Yes/no | 16/59 | 7/23 | 1.000 |
Ascite | |||
Yes/no | 71/4 | 30/0 | 0.470 |
AKI | |||
Yes/no | 13/62 | 7/23 | 0.479 |
MELD score | 24.81 ± 6.68 | 26.10 ± 5.68 | 0.355 |
AARC score | 8.68 ± 1.85 | 9.27 ± 1.82 | 0.143 |
ALBI score | − 1.04 ± 0.45 | − 1.04 ± 0.44 | 0.830 |